Otsuka Holdings Co., Ltd. Provides Consolidated Earnings Guidance for the First Half and Full Year of Fiscal Year Ending December 31, 2024
February 16, 2024 at 01:30 am EST
Share
Otsuka Holdings Co., Ltd. provided consolidated earnings guidance for the first half and full year of fiscal year ending December 31, 2024. For the first half, the company expects revenue to be JPY 1,037,000 million, operating profit to be JPY 168,000 million, profit to be JPY 128,000 million and basic EPS to be JPY 232.17.
For the full year, the company expects revenue to be JPY 2,140,000 million, operating profit to be JPY 330,000 million, profit to be JPY 254,000 million and basic EPS to be JPY 460.67.
Otsuka Holdings Co, Ltd. is a holding company organised around 4 areas of activity:
- manufacture and sale of pharmaceutical products (65.2% of sales): prescription drugs and intravenous solutions mainly for the treatment of central nervous system disorders, cancer, cardiovascular, gastrointestinal and ophthalmic diseases. In addition, the group sells diagnostic products and medical devices;
- manufacture and sale of nutraceutical products (25.1%): functional foods and beverages, OTC products, nutritional supplements;
- production of mineral waters, beverages and foods (2.1%);
- other (7.5%): manufacture of functional chemicals and fine chemicals, provision of logistics services, manufacture of electronic products, etc.
Net sales by source of income are divided between sales of products (93.8%), sales of licences and royalties (1.8%) and other (4.4%).
Net sales are distributed geographically as follows: Japan (43.2%), North America (34%),
OTSUKA HOLDINGS CO., LTD. 
